Just four months after closing its $1.75 billion acquisition of Agila Specialties, generic drug maker Mylan is eyeing another takeover candidate--Sweden's Meda AB. Pennsylvania-based Mylan is talking with advisers about a takeover bid that could be made at a "significant premium" to Meda's $4.5 billion market value, according to sources quoted by the Financial Times.
Generic drug maker Mylan turned itself into one of the largest makers of sterile injectable drugs last year with its $1.75 billion acquisition of Agila Specialties. Today the drugmaker pointed to one reason to take on all of that production capacity. Its earnings got a big boost from injectable products, in part because of drug shortages.
Labeling problems can lead to a recall, particularly when a drug is missing its expiration date labels--or some of the paper label pieces end up in vials. That is the scenario Mylan faces in recalling products made by Agila Specialties, the injectable drug company it bought last year for $1.7 billion.
Mylan's buyout of Agila Specialties from India's Strides Arcolab hit a hitch after the FDA issued a warning letter to one of Agila's plants. Mylan said it was holding back $250 million of the $1.75 billion payout until the regulatory issues get resolved.
Mylan's $1.6 billion deal to buy the sterile injectable business of Strides Arcolab gets all the attention, but the company has expanded in India with several other small acquisitions on top of the big deal for Agila Specialties.
India also has signed off on Mylan's deal to buy the injectable unit from Strides Arcolab. The company reportedly agreed there to maintain the production of certain drugs in India that Agila currently manufacturers.
India's Strides Arcolab some weeks back let the markets know it had received a Form 483 from U.S. regulators for one of its Indian plants, but it insisted it was on top of the problems. Whatever steps being taken were not enough, however, to keep the FDA from issuing a warning letter, which Strides announced Monday.
Trade Minister Anand Sharma said deals on the table will be approved, but the government also will consider putting new restrictions on direct foreign investment to make sure generic versions of some critical drugs remain available.
According to a new report from consultant PwC, there was a decline in the two Vs--volume and value--after some big deals in the first quarter pushed both of those up.
Mylan has boosted manufacturing in India significantly in the 7 years it has been a player there, and wants Indian authorities to understand that much of its further expansion of production will be focused the Indian market.